This will take effect October 20, 2014
Overview and Clinical Utility:
PathGroup is pleased to announce the availability of the FDA-approved Roche cobas® HPV assay effective Monday, October 20. This high-risk HPV test will replace the current Digene Hybrid Capture 2 assay. The new test will be performed on the fully automated cobas® 4800 System, for delivery of trustworthy results with PathGroup’s industry-leading turnaround time.
Click Here to read more.